GILD Stock Price Today (July 2026) — GILD Analysis & Key Metrics 2026-07-17
GILD (GILD) is trading at $134.28, down 1.48% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Software growth opportunities.
- According to consensus analyst estimates, the 1-year price target is N/A (Target pending).
- Volatility remains elevated (32.15% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (N/A% YoY) alongside significant competitive pressures.
GILD Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
GILD - Historical Price & Volume
Market Cap
Enterprise Value: N/A
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
Target analysis pending
Key Investor Questions About GILD
What investors need to know before buying
Based on current market data, GILD presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 58.55)
- Fundamentals say: Mixed signals (nuanced financial profile)
GILD's growth trajectory depends on its ability to expand within the Software sector while managing margin pressures.
- Future growth will depend on performance in core Software operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GILD investors include debt exposure and competitive dynamics in the Software industry.
- N/A in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Software.
52-Week Trading Range
Over the past year, GILD stock traded between N/A and N/A—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.15% annualized volatility and β=0.39, the stock exhibits low sensitivity to market moves—making GILD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?
Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions
Prediction market Kalshi is allowing users to bet on the outcomes of clinical trials and U.S. Food and Drug Adminis...
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.
Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
Gilead's expansion beyond HIV therapies will surprise many investors.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.
Frequently Asked Questions
Common investor questions about GILD
GILD (GILD) is currently trading at $134.28. The RSI (14-day) is at 58.5, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. Volatility is moderate at 32.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for GILD (GILD): The trailing P/E ratio is not available (the company may not be profitable). Valuation should be compared to Software industry peers for context, as different sectors trade at different multiples.
There is currently no consensus analyst price target available for GILD. The stock is currently trading at $134.28. Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
GILD (GILD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for GILD (GILD) investors include: 1. Moderate volatility (32.1% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Software sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Detailed debt information is not currently available for GILD (GILD). Investors should review the company's financial statements directly for the most up-to-date debt figures.